FILANA THERAPEUTICS, INC. (FLNA) Form 10-Q — Jul 29, 2026
Filana Therapeutics reported a net loss of $18.9 million for the six months ended June 30, 2026, a substantial decrease from the $67.6 million loss in the prior year period. The reduction was primarily due to the completion of the phase-out of the company’s Alzheimer’s disease program and the absence of a $31.3 million litigation loss contingency that was recorded in the first half of 2025. As of June 30, 2026, the company held cash and cash equivalents of $82.7 million. The company's lead product candidate, simufilam, remains on full clinical hold by the FDA for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, a status initially received in December 2025.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Cash Position
- 82681000
- Post Period Litigation Payment
- 31250000
Price after filing
Close on the filing date to close N calendar days later (from $0.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.